Open Source Securities released a research report on April 15 stating that it gave Nootai Biotech (688076.SH) a purchase rating. The main reasons for the rating include: 1) leading peptide racetrack companies with a full industrial chain layout, opening up room for growth; 2) GLP-1 blockbuster products are frequently released, catalyzing the boom in the peptide industry chain; 3) the production capacity of peptide APIs has reached the tonnage scale, and downstream demand continues to rise and the growth momentum is strong. (Mainichi Keizai Shimbun)
开源证券4月15日发布研报称，给予诺泰生物（688076.SH）买入评级。评级理由主要包括：1）全产业链布局的多肽赛道龙头企业，自选产品业务快速放量打开成长空间；2）GLP-1重磅单品频出，催化多肽产业链蓬勃发展；3）多肽原料药产能已达吨级规模，下游需求持续提升增长势头强劲。（每日经济新闻）
Open Source Securities released a research report on April 15 stating that it gave Nootai Biotech (688076.SH) a purchase rating. The main reasons for the rating include: 1) leading peptide racetrack companies with a full industrial chain layout, opening u
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.